N-terminal pro-brain natriuretic peptide is related with coronary flow velocity reserve and diastolic dysfunction in patients with asymmetric hypertrophic cardiomyopathy.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Cardiology

• Publication date

  2017-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jjcc.2017.02.008PMID 28336204
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.

  2016cited by this paper
• Whole exome sequencing combined with integrated variant annotation prediction identifies a causative myosin essential light chain variant in hypertrophic cardiomyopathy.

  2016cited by this paper
• Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: The International Stress Echo Registry.

  2016cited by this paper
• Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

  2015cited by this paper
• Prognostic value of calcium score and coronary flow velocity reserve in asymptomatic diabetic patients

  2015cited by this paper
• The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI

  2015cited by this paper
• Time-dependent changes of plasma adiponectin concentration in relation to coronary microcirculatory function in patients with acute myocardial infarction treated by primary percutaneous coronary intervention.

  2015cited by this paper
• Prognostic role of coronary flow reserve for left ventricular functional improvement after cardiac resynchronization therapy in patients with dilated cardiomyopathy.

  2014cited by this paper
• 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

  2014cited by this paper
• [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy].

  2014cited by this paper
• Subendocardial ischemia in hypertrophic cardiomyopathy.

  2014cited by this paper
• Regional difference of microcirculation in patients with asymmetric hypertrophic cardiomyopathy: transthoracic Doppler coronary flow velocity reserve analysis.

  2013cited by this paper
• Estimation of infarct size using transthoracic Doppler echocardiographic measurement of coronary flow reserve in infarct related and reference coronary artery.

  2013cited by this paper
• Tissue doppler imaging and plasma BNP levels to assess the prognosis in patients with hypertrophic cardiomyopathy.

  2011cited by this paper
• Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides.

  2011cited by this paper
• Determinants of elevated NT-proBNP levels in patients with hypertrophic cardiomyopathy: an echocardiographic study.

  2009cited by this paper
• The case for myocardial ischemia in hypertrophic cardiomyopathy.

  2009cited by this paper
• Prognostic implications of coronary flow reserve on left anterior descending coronary artery in hypertrophic cardiomyopathy.

  2008cited by this paper
• N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization.

  2008cited by this paper
• Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging.

  2008cited by this paper
• Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

  2008cited by this paper
• Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics

  2007cited by this paper
• Prognostic value of coronary flow reserve in medically treated patients with left anterior descending coronary disease with stenosis 51% to 75% in diameter.

  2007cited by this paper
• Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy.

  2007cited by this paper
• N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

  2005cited by this paper
• Impact of right atrial-left ventricular dual-chamber permanent pacing in patients with severely symptomatic hypertrophic obstructive cardiomyopathy.

  2005cited by this paper
• Usefulness of B-Type Natriuretic Peptide Assay in the Assessment of Symptomatic State in Hypertrophic Cardiomyopathy

  2004cited by this paper
• Transthoracic echocardiographic evaluation of coronary flow reserve in patients with hypertrophic cardiomyopathy.

  2004cited by this paper
• The pathology of hypertrophic cardiomyopathy

  2004cited by this paper
• Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

  2003cited by this paper
• Increased cardiac BNP expression associated with myocardial ischemia

  2003cited by this paper
• B Type natriuretic peptide: a good omen in myocardial ischaemia?

  2003cited by this paper
• N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes

  2002cited by this paper
• Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy.

  2002cited by this paper
• Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy.

  2001cited by this paper
• Transient increase in plasma brain (b‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty

  2000cited by this paper
• Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease

  2000cited by this paper
• Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy.

  1999cited by this paper
• Dipyridamole echocardiography for diagnosis of coexistent coronary artery disease in hypertrophic cardiomyopathy. Echo-Persantine International Cooperative (EPIC) Study Group--Subproject Hypertrophic Cardiomyopathy.

  1995cited by this paper
• Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease.

  1979cited by this paper

• The Diagnostic Significance of Circulating Eicosanoid in Patients with Hypertrophic Cardiomyopathy

  2025cites this paper
• The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis

  2025cites this paper
• Systemic Manifestations of COPD and the Impact of Dual Bronchodilation with Tiotropium/Olodaterol on Cardiac Function and Autonomic Integrity

  2024cites this paper
• The Role of Nt-Pro-Bnp in Predicting Outcome in Pediatric Hypertrophic Cardiomyopathy

  2024cites this paper
• Kegunaan BNP dan NT-proBNP sebagai Diagnostic Biomarkers pada Gagal Jantung dan Disfungsi Jantung dalam Bidang Klinis dan Forensik

  2024cites this paper
• Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion

  2023cites this paper
• Prognostic Value of Mitral Regurgitation in Patients with Primary Hypertrophic Cardiomyopathy

  2023cites this paper
• Use of 3D Printing Techniques to Fabricate Implantable Microelectrodes for Electrochemical Detection of Biomarkers in the Early Diagnosis of Cardiovascular and Neurodegenerative Diseases

  2023cites this paper
• Coronary Flow Velocity Reserve by Echocardiography: Beyond Atherosclerotic Disease

  2023cites this paper
• Association of NT-proBNP and hs-cTnT with Imaging Markers of Diastolic Dysfunction and Focal Myocardial Fibrosis in Hypertrophic Cardiomyopathy

  2022cites this paper
• Circulating Biomarkers in Hypertrophic Cardiomyopathy

  2022cites this paper
• Role of different echocardiographic modalities in the assessment of microvascular function in women with ischemia and no obstructive coronary arteries

  2022cites this paper
• Determinants of Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

  2022cites this paper
• Expression of miR-93-5p as a Potential Predictor of the Severity of Chronic Thromboembolic Pulmonary Hypertension

  2021cites this paper
• Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy

  2021cites this paper
• Decreased circulating follicular regulatory T cells in patients with dilated cardiomyopathy

  2021cites this paper
• Impairment of coronary flow velocity reserve and global longitudinal strain in women with cardiac syndrome X and slow coronary flow.

  2020cites this paper
• Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction

  2020cites this paper
• Is microvascular dysfunction a systemic disorder with common biomarkers found in the heart, brain, and kidneys? - a scoping review.

  2020cites this paper
• Elevated level of N-terminal pro B-type natriuretic peptide is associated with myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction

  2020cites this paper
• The feasibility and diagnostic value of intravoxel incoherent motion diffusion-weighted imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy patients.

  2020cites this paper
• Identifying Cardiac Diseases using Cardiac Biomarkers in Rhesus Macaques (Macaca mulatta).

  2020cites this paper
• BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine

  2019cites this paper
• Hypertrophic Cardiomyopathy: The Time-Synchronized Relationship between Ischemia and Left Ventricular Dysfunction Assessed by Highly Sensitive Troponin I and NT-proBNP

  2019cites this paper
• Serum N‑terminal pro-brain natriuretic peptide as a prognostic marker in patients with hypertrophic cardiomyopathy.

  2019cites this paper
• Combined mechanical mitral valve replacement and transmitral myectomy for hypertrophic obstructive cardiomyopathy treatment: An experience of over 20 years.

  2019cites this paper
• Pregnancy outcomes and mid-term prognosis in women after arterial switch operation for dextro-transposition of the great arteries - Tertiary hospital experiences and review of literature.

  2019cites this paper
• Prognostic Value of Preserved Coronary Flow Velocity Reserve by Noninvasive Transthoracic Doppler Echocardiography in Patients With Angiographically Intermediate Left Main Stenosis

  2019cites this paper
• Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients with Nonculprit Stenosis of Intermediate Severity Early after Primary Percutaneous Coronary Intervention

  2018cites this paper
• Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease

  2018cites this paper
• Significance of relative coronary flow reserve in patient with microvascular dysfunction to differentiate significant coronary artery stenosis

  2017cites this paper
• Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice.

  2017cites this paper
• The impact of tissue Doppler index E/e' ratio on instantaneous wave-free ratio.

  2017cites this paper